EXPERT KNOWLEDGE
IN RARE DISEASES, CELL
AND GENE THERAPY
With decades of combined experience, we can help
you through every step of your journey taking
your orphan drug to market
Find out more about us
IT’S IN OUR NATURE
TO CARE ABOUT YOU
We have highly experienced team members who care
deeply about the rare circumstances of the
conditions and challenges that are faced.
Meet the team
ROBUST AND
RIGOUR IN OUR
DELIVERABLES
Always under the microscope, we are judged
on our results, and we thrive on that, click
below to find out
What our clients say about us

Expert global consultancy specializing in access for orphan drugs, cell and gene therapy

At Partners4Access, we believe in striking an equilibrium in the orphan drug, cell and gene therapy world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.

A GLOBAL COMPANY WITH GLOBAL REACH

As a global company, we don’t just provide access services, we partner with our clients to help them achieve their PR&MA goals. A large part of that involves us supporting the right strategic and investment decisions. If you want to increase your success in launching an orphan drug at the right price and access conditions, Partners4Access are the right team for you.

Find Out More

Many thanks to you and the Partners4Access team. Another project very well completed.

Director Europe, Otsuka

Partners4Access has carried out successful pricing projects for me three times and I expect to use them again.

VP Market Access and HEOR, Deciphera

I very much appreciated the thoughtful approach your team took to this complicated project. Your synthesized analysis was tightly tailored to my company’s particular challenges, and gave us a clear path forward; a clear contrast to some other external partners who seem to recycle content across clients.

Senior Director, Blue Chip Pharma

P4A has helped us prepare for our orphan drug launch, supporting us for over 2 years. The team is always a pleasure and easy to work with; and what’s more they truly understand our needs in the rare disease space.

Senior Director, GW Pharmaceuticals

LATEST NEWS